Status:
COMPLETED
Study Evaluating Isovorin in Colon Cancer
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Colon Cancer
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease...
Eligibility Criteria
Inclusion
- Dukes C, Cure A colon cancer diagnosed histologically or cytologically
- Normal organ function of bone marrow, heart, liver and kidney
- Age 20-75
- Other inclusion applies
Exclusion
- Serious bone marrow suppression, infection, heart disease or complication
- Familial adenomatous polyposis or hereditary nonpolyposis
- Pregnant or breastfeeding women
- Other exclusion applies
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT00195585
Start Date
October 1 2002
End Date
February 1 2006
Last Update
August 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo, Japan, 104-0031